Momenta Pharmaceuticals to Present at The 2005 Pacific Growth Equities Life Sciences Growth Conference
CAMBRIDGE, Mass., June 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Michael A. Lawless, Senior Director Investor Relations, will present at the 2005 Pacific Growth Equities Life Sciences Growth Conference on Monday, June 6, 2005 at 10:30 am PDT at the InterContinental Mark Hopkins Hotel, San Francisco, CA
Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic versions of sugar-based and biologic drug products. The Company's most advanced product candidate is M-Enoxaparin, a technology-enabled generic version of Lovenox®. Based on its understanding of complex sugars, Momenta has created a diversified pipeline of near-term product opportunities, novel development products and discovery candidates. Momenta was founded in 2001 and is headquartered in Cambridge, MA.
To receive additional information about Momenta, please visit our website at http://www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners and are not the property of Momenta Pharmaceuticals, Inc.
Michael A. Lawless
Momenta Pharmaceuticals, Inc.
SOURCE Momenta Pharmaceuticals, Inc.
Michael A. Lawless of Momenta Pharmaceuticals, Inc., +1-617-395-5189